Trial Profile
Deoxythymidine and Deoxycytidine Treatment for Thymidine Kinase 2 (TK2) Deficiency
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Deoxycytidine/deoxythymidine (Primary)
- Indications Mitochondrial disorders
- Focus Therapeutic Use
- 27 Nov 2023 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.
- 27 Nov 2023 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2025.
- 28 Jul 2022 Status changed from recruiting to active, no longer recruiting.